Compare Novartis AG (NVS) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs iShares Silver Trust — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while iShares Silver Trust trades at $54.49 (market cap $29.58B). The key difference: Novartis AG is far larger — about 9.3× iShares Silver Trust's market cap, and Novartis AG pays a 3.31% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and iShares Silver Trust for 89 Days on average.
| NVS | SLV | |
|---|---|---|
Market Cap | $274.00B | $29.58B |
Volume | 1,852,137 | 20,364,955 |
Sector | Health | — |
52-Week High | $168.62 | $105.57 |
52-Week Low | $121.80 | $42.40 |
Typical Hold Time | 82 Days | 89 Days |
Enterprise Value | $315.32B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% amid broader precious metals pressure from rising Treasury yields and Fed rate hike expectations. The ETF shows minimal operational activity with $0 revenue but maintains a strong balance sheet with $13.41 billion in assets against negligible liabilities. Technical indicators signal bearish momentum with moving averages overwhelmingly negative, though RSI levels suggest potential oversold conditions.
While silver faces near-term headwinds from monetary policy, structural demand from industrial applications and inflation hedging provides long-term support. Key risks include Fed policy volatility and dollar strength, but the trust's pure-play silver exposure offers strategic diversification. Current levels may present accumulation opportunities for investors with multi-year horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
